Title : Oral Drugs Against COVID-19–Management of Drug Interactions With the Use of Nirmatrelvir/Ritonavir.

Pub. Date : 2022 Apr 15

PMID : 35302484






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 (CYP) 3A in the gut and liver. Arginine cytochrome P450 family 4 subfamily F member 3 Homo sapiens